Alto Neuroscience, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Alto Neuroscience, Inc. (ANRO) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $403.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-12
- Alto Neuroscience, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $203.00K, a 5.73% increase year-over-year.
- Alto Neuroscience, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $200.00K, a 5.26% increase year-over-year.
- Alto Neuroscience, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $197.00K, a 6.64% decline year-over-year.
- Alto Neuroscience, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $195.00K.
- Alto Neuroscience, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $774.00K, a 129.67% increase from fiscal 2024.
- Alto Neuroscience, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $337.00K, a 20.36% increase from fiscal 2023.
- Alto Neuroscience, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $280.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $203.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $403.00K 10-Q · filed 2026-08-12 | $600.00K derived: sum of 3 quarters · filed 2026-08-12 | $795.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $200.00K 10-Q · filed 2026-05-13 | $397.00K derived: sum of 2 quarters · filed 2026-05-13 | $592.00K derived: sum of 3 quarters · filed 2026-05-13 | $784.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $197.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $392.00K derived: sum of 2 quarters · filed 2026-03-16 | $584.00K derived: sum of 3 quarters · filed 2026-08-12 | $774.00K 10-K · filed 2026-03-16 |
| 2025-09-30 | $195.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $387.00K derived: sum of 2 quarters · filed 2026-08-12 | $577.00K 10-Q · filed 2025-11-12 | $788.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $192.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $382.00K 10-Q · filed 2026-08-12 | $593.00K derived: sum of 3 quarters · filed 2026-08-12 | $593.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $190.00K 10-Q · filed 2026-05-13 | $401.00K derived: sum of 2 quarters · filed 2026-05-13 | $401.00K derived: sum of 3 quarters · filed 2026-05-13 | $455.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $211.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $211.00K derived: sum of 2 quarters · filed 2026-03-16 | $265.00K derived: sum of 3 quarters · filed 2026-03-16 | $337.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $54.00K derived: sum of 2 quarters · filed 2025-11-12 | $126.00K 10-Q · filed 2025-11-12 | $197.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $54.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $126.00K 10-Q · filed 2025-08-13 | $197.00K derived: sum of 3 quarters · filed 2025-08-13 | $262.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $72.00K 10-Q · filed 2025-05-14 | $143.00K derived: sum of 2 quarters · filed 2025-05-14 | $208.00K derived: sum of 3 quarters · filed 2025-05-14 | $277.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $71.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $136.00K derived: sum of 2 quarters · filed 2025-03-20 | $205.00K derived: sum of 3 quarters · filed 2025-03-20 | $280.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $65.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $134.00K derived: sum of 2 quarters · filed 2024-11-12 | $209.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $69.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $144.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $75.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |